Read more stories about
Montana Biotech >>

MATR Sponsor:

MATR Supporters:

Glaxo to Get Up to $200 Million From U.S. for Biothreat Research

June 1, 2013View for printing

GlaxoSmithKline Plc (GSK), the U.K.'s largest drugmaker, will work with the U.S. government to develop antibiotics for resistant infections and bioterrorist threats in an agreement valued at as much as $200 million.

By Makiko Kitamura and Olivia Sterns

Full Story: ... at-research
No reader comments so far. Be the first to comment by clicking the button below.

Reprinted under the Fair Use doctrine of international copyright law. Full copyright retained by the original publication. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

E-mail this page to a friend!